Code intelligence

FDA-BLA125514 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance referencing code FDA-BLA125514.

Critical code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Critical

Critical

100%

High

Routine

Low

New this month

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: KEYTRUDA (PEMBROLIZUMAB) — Type 1 - New Molecular Entity

Policy FDA-BLA125514 · Oncology

Critical

Keytruda (pembrolizumab) is an injectable drug that is administered intravenously, likely to receive a J-code for billing under Medicare Part B. Given its classification as an orphan drug and its rele

View alert